Literature DB >> 20156922

Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question.

Rossella Elisei1, Eleonora Molinaro, Laura Agate, Valeria Bottici, Lucio Masserini, Claudia Ceccarelli, Francesco Lippi, Lucia Grasso, Fulvio Basolo, Generoso Bevilacqua, Paolo Miccoli, Giancarlo Di Coscio, Paolo Vitti, Furio Pacini, Aldo Pinchera.   

Abstract

BACKGROUND: In the last decades, a marked increased prevalence of differentiated thyroid cancer (DTC) has been observed worldwide. The aim of this study was to evaluate the changing features of DTC referred to our institution between 1969 and 2004.
METHODS: Clinical and pathological features and prognostic factors were analyzed in 4187 DTC patients, subdivided into two groups: group 1 (n = 1215) and group 2 (n = 2972) diagnosed before and after 1990, respectively.
RESULTS: Group 2 showed an increased proportion of micropapillary carcinoma and a concomitant decrease of follicular histotype. Male percentage was greater in group 2, whereas median age at diagnosis was unchanged. DTC of group 2 were more frequently associated with multinodular goiter or autoimmune thyroiditis, but many were unexpected findings. Features of aggressiveness were significantly less frequent in group 2, and the survival rate was greater (98.7 vs. 91.4%, P < 0.0001). Gender, age, histotype, tumor size, extrathyroidal macroinvasion, and lymph node and/or distant metastases were found to be poor prognostic factors in both groups using univariate analysis, but with multivariate analysis, only advanced age (odds ratio = 22.52 for older patients) and advanced stage (odds ratio = 53.54 for more advanced cases) were independently correlated with a lower survival.
CONCLUSIONS: DTC patients diagnosed after 1990 have smaller tumors with less advanced stage and a better prognosis. The question of whether this is related to the finding of tumors with a low clinical penetrance or to the anticipation of diagnosis remains to be clarified. Despite these significant differences, both advanced stage and older age still represent the most important poor prognostic factors for survival.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20156922     DOI: 10.1210/jc.2009-1536

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  62 in total

1.  Clinical-pathological changes in differentiated thyroid cancer (DTC) over time (1997-2010): data from the University Hospital "Maggiore della Carità" in Novara.

Authors:  L Pagano; M Caputo; M T Samà; V Garbaccio; M Zavattaro; M G Mauri; F Prodam; P Marzullo; R Boldorini; G Valente; G Aimaretti
Journal:  Endocrine       Date:  2012-10       Impact factor: 3.633

2.  Appropriate and accurate diagnosis of thyroid nodules: a review of thyroid fine-needle aspiration.

Authors:  Catherine Hambleton; Emad Kandil
Journal:  Int J Clin Exp Med       Date:  2013-06-26

3.  Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012.

Authors:  Aubrey A Carhill; Danielle R Litofsky; Douglas S Ross; Jacqueline Jonklaas; David S Cooper; James D Brierley; Paul W Ladenson; Kenneth B Ain; Henry G Fein; Bryan R Haugen; James Magner; Monica C Skarulis; David L Steward; Mingxhao Xing; Harry R Maxon; Steven I Sherman
Journal:  J Clin Endocrinol Metab       Date:  2015-07-14       Impact factor: 5.958

4.  Cytological diagnosis of follicular carcinoma thyroid metastasis in pelvic muscles-a rare and unusual site.

Authors:  Sanjay Piplani; Rahul Mannan; Tejinder Singh Bhasin; Mridu Manjari; Karamjit Singh Gill
Journal:  J Clin Diagn Res       Date:  2014-07-20

5.  Molecular profiles of papillary thyroid tumors have been changing in the last decades: how could we explain it?

Authors:  Rossella Elisei
Journal:  J Clin Endocrinol Metab       Date:  2014-02       Impact factor: 5.958

6.  How do etiological factors can explain the different clinical features of patients with differentiated thyroid cancer and their histopathological findings?

Authors:  Loredana Pagano; Chiara Mele; Debora Arpaia; Maria Teresa Samà; Marina Caputo; Serena Ippolito; Carmela Peirce; Flavia Prodam; Guido Valente; Giuseppe Ciancia; Gianluca Aimaretti; Bernadette Biondi
Journal:  Endocrine       Date:  2016-05-26       Impact factor: 3.633

Review 7.  New insights in risk stratification of differentiated thyroid cancer.

Authors:  Maria Papaleontiou; Megan R Haymart
Journal:  Curr Opin Oncol       Date:  2014-01       Impact factor: 3.645

Review 8.  [Surgical therapy for thyroid gland malignancies].

Authors:  P E Goretzki; K Schwarz; B Lammers
Journal:  HNO       Date:  2013-01       Impact factor: 1.284

9.  BRAF mutation correlates with recurrent papillary thyroid carcinoma in Chinese patients.

Authors:  F J Huang; W Y Fang; L Ye; X F Zhang; L Y Shen; R L Han; Q Wei; X C Fei; X Chen; W Q Wang; S Wang; G Ning
Journal:  Curr Oncol       Date:  2014-12       Impact factor: 3.677

10.  Changes in the clinicopathological characteristics and outcomes of thyroid cancer in Korea over the past four decades.

Authors:  Bo Youn Cho; Hoon Sung Choi; Young Joo Park; Jung Ah Lim; Hwa Young Ahn; Eun Kyung Lee; Kyung Won Kim; Ka Hee Yi; June-Key Chung; Yeo-Kyu Youn; Nam Han Cho; Do Joon Park; Chang-Soon Koh
Journal:  Thyroid       Date:  2013-06-21       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.